Ionetix Goes Public to Fuel Medical Isotope and Energy Tech Boom

LANSING, MI – April 21, 2026 – Particle accelerator specialist Ionetix has secured over $30 million in new funding and completed a go-public transaction, positioning the company to aggressively scale its production of critical medical isotopes and expand its advanced technology into new industrial sectors.

The Lansing-based company announced today it had finalized the major financing through a private placement offering at $3.00 per share. Concurrently, Ionetix completed a reverse merger with the special purpose acquisition company JDEV Acquisition Corp., which has now been renamed Ionetix Corp. This strategic maneuver provides a significant capital injection and a direct path to the public markets, where the company intends to seek a quotation on the OTCQB Venture Market.

A Strategic Leap to the Public Market

The dual transaction marks a pivotal moment for Ionetix, transforming it from a private enterprise into a publicly reporting entity under the Securities Exchange Act of 1934. This transition not only provides the financial muscle for its ambitious growth plans but also introduces a new level of transparency and access for investors. The company plans to file a resale registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) to register its shares.

"With this financing and a path toward becoming a publicly traded company, we will continue scaling up production of medical radioisotopes as well as increase our R&D efforts for our particle accelerator platform technology in the nuclear energy, materials testing and other related spaces," said Kevin Cameron, Chief Executive Officer of Ionetix, in a statement.

The move is designed to capitalize on what the company sees as a burgeoning opportunity in nuclear medicine and beyond. By entering the public markets, Ionetix gains access to a broader pool of capital necessary to fund costly manufacturing scale-ups and long-term research and development initiatives. The financing was managed by Network 1 Financial Securities, Inc., with consultation from Intuitive Ventures Partners LLC.

Powering the Future of Nuclear Medicine

Ionetix enters the public sphere at a critical inflection point for the medical isotopes market. This sector, valued at nearly $6 billion in 2024, is on a steep growth trajectory, with projections estimating it could reach between $8.8 billion and $14.9 billion by 2035. This expansion is fueled by an aging global population, a rising incidence of chronic diseases like cancer and heart disease, and significant advancements in medical imaging and therapy.

The company is already generating revenue from two of the market's most dynamic segments: positron emission tomography (PET) diagnostics and alpha emitter therapeutics. PET imaging provides crucial diagnostic information for early disease detection, while alpha emitter therapies represent a revolutionary approach to cancer treatment. This field of targeted radionuclide therapy is experiencing explosive growth, with some market forecasts projecting a compound annual growth rate (CAGR) exceeding 23% and a market size of over $4.6 billion by 2030. Alpha emitters deliver highly potent, localized radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.

Ionetix is strategically positioned to supply this demand, producing high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211)—two of the most promising isotopes for targeted alpha therapy. The company has already announced successful production at its new Alpha Isotope Manufacturing facility in Lansing, signaling its intent to become a key domestic supplier and help mitigate the fragile global supply chain for these life-saving materials.

The Superconducting Cyclotron Advantage

At the heart of Ionetix's strategy is its proprietary, patent-protected superconducting cyclotron technology. Unlike traditional, room-sized particle accelerators, Ionetix's systems are remarkably compact and energy-efficient. This is exemplified by its flagship ION-12SC, a 12 MeV proton superconducting cyclotron.

Superconducting magnets allow the device to generate powerful magnetic fields within a much smaller footprint, drastically reducing the physical space, infrastructure, and radiation shielding required. This makes it feasible to install the cyclotrons directly within or near hospital campuses, enabling on-demand, localized production of radiopharmaceuticals. This "point-of-care" production model is a game-changer for isotopes with extremely short half-lives, which cannot be stockpiled and are vulnerable to logistical delays.

By decentralizing production, the ION-12SC directly addresses long-standing vulnerabilities in the radiopharmaceutical supply chain, which has historically relied on a handful of aging, often foreign-based nuclear reactors. Ionetix has already established a network of these units at leading institutions, including the University of Michigan Medical School, demonstrating their reliability and high-yield production capabilities for isotopes used in cardiac PET diagnostics and other imaging procedures.

Beyond Medicine: New Frontiers in Energy and Materials

While nuclear medicine is its current focus, Ionetix is leveraging its new funding to look toward broader industrial applications. The company's press release highlighted plans to increase R&D in the nuclear energy and materials testing sectors, where particle accelerators are indispensable tools.

In materials science, accelerators are used for everything from hardening industrial components and fabricating semiconductors to non-destructively analyzing the integrity of aerospace parts. In the energy sector, they are crucial for researching the properties of materials under extreme conditions, a key factor in developing next-generation nuclear reactors and advanced energy storage solutions.

This diversification strategy allows Ionetix to leverage its core competency in particle accelerator design and manufacturing across multiple high-value industries. While these initiatives are in the R&D phase, they represent a significant long-term growth opportunity, transforming Ionetix from a specialized medical supplier into a broader industrial technology platform.

Navigating a Complex Landscape

The path forward, while promising, is not without significant challenges. The company operates in a highly regulated and competitive environment. Gaining and maintaining approvals from bodies like the FDA and the Nuclear Regulatory Commission (NRC) is a complex and continuous process. Furthermore, the forward-looking statements in its announcement acknowledge several risks, including a history of losses and reliance on a limited supply of key raw materials.

The short half-life of its core products creates unique manufacturing and logistical pressures that demand precision and flawless execution. However, the company's core strategy of deploying a distributed network of compact cyclotrons is itself a direct response to these inherent challenges. By bringing isotope production closer to the patient, Ionetix aims to build a more resilient and efficient supply chain. As the company prepares its formal S-1 registration with the SEC, both the medical and investment communities will be watching closely to see if its ambitious technological vision can translate into sustained market success.